Sanofi is investing EUR 350 million ($431 million) for the construction of a new vaccine-manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. 

The new facility will allow Sanofi Pasteur, the global vaccines business unit of Sanofi, to meet growing demand of a five-component acellular pertussis (5-acP) antigen. Upon completion in 2021, the new building will also be equipped to produce the antigens used in diphtheria and tetanus vaccines.

Sanofi has 11 sites for the industrial operations of Sanofi Pasteur in vaccines, according to the company’s 2017 annual filing. These sites are located in the following: Argentina (Pilar);  Canada (Toronto); China (Shenzhen); France: Marcy l’Étoile, Val de Reuil, and Neuville; India (Hyderabad); Mexico (Ocoyoacac); Thailand (Chachoengsao); and the US: Swiftwater, Pennsylvania and Pearl River, New York. In 2017, the company produced 470 million containers (syringes and ampuls) filled of vaccines, including outsourced production.

In 2017, the Sanofi Pasteur (Vaccines) Global Business Unit posted net sales of EUR 5.101 billion ($6.283 billion), a 14.5% increase year over year at constant exchanges rates. It represented 14.5% of total 2017 net sales for the company of EUR 35.055 billion ($43.172 billion). Pharmaceuticals represent the largest piece of Sanofi at 71.7% of net sales or EUR 25.122 billion ($30.948 billion). Consumer healthcare accounts for the balance at 13.8% of 2017 net sales or EUR 4.832 billion ($5.954 billion).

Source: Sanofi